News
Displaying 381–390 of 504
-
jCyte Reports Results for Phase 1/2a Clinical Trial for Retinal-Cell Treatment
Research NewsSome participants reported increased light sensitivity, improved color vision, better mobility, and improved reading ability.
-
History Is Made: FDA Approves Spark's Vision-Restoring Gene Therapy
Research NewsKnown as LUXTURNA™ (voretigene neparvovec), the gene therapy restored vision in a clinical trial for people between the ages of 4 and 44 with Leber congenital amaurosis (LCA) caused by mutations in the gene RPE65.
-
Stem-Cell Therapy Clinics Remain Inadequately Regulated, Pose Risk to Patients
Research NewsIf a clinic is charging for a stem-cell treatment or procedure for an IRD, it is probably not legit. The expense to the patient is a major red flag.
-
ProQR Doses First Participant in Its LCA10 Therapy Clinical Trial
Research NewsThe company plans to report interim, six-month study results in 2018 and 12-month results in 2019.
-
Research News
An advisory committee comprised of FDA-selected experts voted unanimously – 16 to 0 – to recommend approval.
-
Research News
Investigational LUXTURNA has the potential to be both the first pharmacologic treatment for an inherited retinal disease (IRD) and the first gene therapy for a genetic disease in the United States
First adeno-associated viral (AAV) vector investigational candidate to reach this stage of FDA review
Investigational LUXTURNA clinical program includes up to four years of efficacy data, with observation ongoing
-
The Foundation's Investments Are Filling the Pipeline for Vision-Saving Therapies
Research NewsIn addition to funding promising biotech start-ups, the Foundation Fighting Blindness has played a critical role in developing research talent.
-
MeiraGTx Treats First Patient in XLRP Gene-Therapy Trial
Research NewsThe MeiraGTx gene therapy involves injection of healthy copies of RPGR underneath the retina. The RPGR copies are contained in a human-engineered virus — known as an adeno-associated virus or AAV — designed to readily penetrate retinal cells to deliver the therapeutic genetic cargo.
-
Scientists Receive $25 Million to Develop a Vision-Restoring System that Connects to the Brain
Research NewsThe high-tech, vision-restoring system interfaces with the visual cortex, the back of the brain where visual input is processed to create the images we see.
